Objectives: The prevalence of urinary incontinence (UI) in women in Slovakia is about 240 000 cases and has an increasing trend. Only 5 % of them were diagnosed by visiting urology or gynecology outpatient department. The objective of this paper was to find out the level of QoL in women with UI in Slovakia. MethOds: The primary method used for the analysis of QoL was the combined questionnaire consisting of 6 parts: A. Demography (9 items), B. Clinical part (B1-International Consultation on Incontinence (ICIQ-SF): 4 items, B2-characteristics of UI: 23 items), C. Quality of life with dominant numeric scale (13 items), D. Socio-economic part (9 items), E. EQ-5D (5 items), F. Symptoms of disease (9 items). There were 112 patients in the examined group from the160 asked to fill the questionnaire. The average age was 61 years. Results: Present level of QoL was identified as 6,60 on the scale from 1 to 10 (1-the worst,10 -the best), while in the time of the UI diagnosis it was 5,10. QoL was 8,10 in the time without UI and 9,40 in the total optimal state of health. Comparative to the QoL was examined the ability to work (AW), too. Present level of AW was identified as 6,50, while in the time of the BC diagnosis it was 5,50. AW was 8.20 in the time without UI and 9,40 in the total optimal state of health. The impact of treatment on QoL was 7,60 and the disease had impact 7,40 on family QoL. The average income was 465,04 € and the willingness to pay for 1 month of complete health was in average 391,06 € . cOnclusiOns: The disease had a significant impact on patients´s QoL. The treatment of UI had a significant impact on increasing QoL of patients.

No abstract

a patient on LTP with recurrent bleedings. Methods: A cost-consequences analysis was adopted to assess the economic impact from the NHS and Society perspectives. The cost analysis was based on one patient case (type 1 VWD, recurrent gum bleedings), treated with FVIII/VWF and then with VWF concentrate almost devoid of FVIII. The costs included direct costs (drug acquisition, hospital admissions, outpatient visits, red blood cells units) and indirect costs (working days lost). Data were gathered from a questionnaire (Hemophilia Reference Center of Catania). The health care costs were calculated by DRG analysis that assessed DRG refund value for day hospital and standard hospitalization. The indirect costs were calculated on the basis of the annual income average. Results: The analysis showed a reduction of the number of bleedings when treating with VWF concentrate almost devoid of FVIII (30 vs 0), minimizing the cost per bleeding episodes (€ 87,957 vs € 0), hospitalizations (€ 3,252 vs 0), monitoring visits (€ 331 vs € 165) and the number of working days lost (26 vs 2). The annual health care costs and indirect costs avoided were € 49,684 and € 3,734 respectively. ConClusions: The replacement therapy with VWF concentrate almost devoid of FVIII decreased the consumption of hospital resources and reduced the number of working days lost per bleedings together with the discomfort related to bleedings.objeCtives: TPO-RAs, represent an evidence-based treatment option in the public setting for adult patients with chronic ITP in Mexico. TPO-RAs have not been directly compared in head-to-head randomized controlled trials (RCTs); however an indirect comparison was undertaken using Bayesian metaregression: the overall platelet response was significantly higher in patients receiving Romiplostim than in those receiving Eltrombopag, estimating an Odds ratio (OR) of eltrombopag vs romiplostim as 0.15 (95% CI: 0.02, 0.84). The objective of this study is to compare the cost per response of TPO-RAs in chronic adult ITP in Mexico. Methods: A cost per response analysis was developed. Dose was derived from RCTs and Summary of Product Characteristics. Median dose for romiplostim was 2.5 mcg/kg/week and average dose for eltrombopag was 55 mg/day (21.5% of patients received 25mg; 41% 75mg; and remaining 37.5% 50mg). Costs for romiplostim were based on vials used, considering a representative Mexican patient (65kg); for eltrombopag, it was based on milligrams needed. Cost assessment included cost of medication, cost of administration and in case of eltrombopag, cost of liver monitoring, expressed in Mexican pesos. Crude Overall Response Rate (ORR) for romiplostim was 83%. Placebo adjusted ORR for eltrombopag was 42% calculated by applying the OR estimated from the Bayesian indirect comparison performed by the NICE Evidence Review Group. Results: Romiplostim generates a cost per overall platelet response of $219,690.80, while eltrombopag yields $374,137.72. ConClusions: Within the TPO-RAs, romiplostim generates a lower cost per response tha...